Pimecrolimus
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Pimecrolimus: From Atopic Eczema to Seborrheic Dermatitis
One-Sentence Summary
Pimecrolimus is a topical calcineurin inhibitor, originally used to treat atopic eczema (atopic dermatitis). The TxGNN model predicts it may be effective for Seborrheic Dermatitis, with 1 completed Phase 2 clinical trial and 19 publications (including 2 systematic reviews of randomized trials) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic eczema / atopic dermatitis (the Singapore licence record contains no approved indication text) |
| Predicted New Indication | Seborrheic dermatitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. From the published literature, pimecrolimus is a topical calcineurin inhibitor. It blocks T-cell activation, reduces release of inflammatory cytokines (IL-2, IL-4, interferon-gamma, TNF-alpha), and inhibits mast cell degranulation. It is designed for skin application, with low systemic absorption.
Atopic dermatitis and seborrheic dermatitis are both chronic, relapsing inflammatory skin diseases that affect areas such as the face. Seborrheic dermatitis is also linked to an inflammatory response to Malassezia yeast on the skin. Because pimecrolimus suppresses T-cell-driven inflammation, it is mechanistically reasonable for this condition. It also avoids the long-term adverse effects of topical corticosteroids, which limit their use on the face. Systematic reviews of randomized trials report that pimecrolimus 1% cream is well tolerated and effective for facial seborrheic dermatitis, with efficacy comparable to the comparators examined.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00403559 | Phase 2 | Completed | 113 | 4-week randomized, double-blind, active-comparator study of Elidel (pimecrolimus) in seborrheic dermatitis; exploratory study of effectiveness |
This is the only registered trial directly in seborrheic dermatitis. It is short and Phase 2 only. Many additional Phase 3 and 4 trials exist for atopic dermatitis and other dermatitis types, but they do not address seborrheic dermatitis directly.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22142161 | 2012 | Systematic review of RCTs | Expert Rev Clin Pharmacol | Pimecrolimus 1% cream appears well tolerated and effective for seborrheic dermatitis versus corticosteroids, antimycotics, placebo or no intervention |
| 36072203 | 2022 | Systematic review of RCTs | Cureus | Reviews efficacy and safety of pimecrolimus in facial seborrheic dermatitis |
| 27804089 | 2017 | Systematic review | Am J Clin Dermatol | Reviews topical treatments (antifungals, keratolytics, corticosteroids) for facial seborrheic dermatitis |
| 31053034 | 2019 | Review | J Cutan Med Surg | Reviews off-label uses of topical pimecrolimus, focusing on published RCTs |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Topical calcineurin inhibitors are a safe alternative to corticosteroids for seborrheic dermatitis |
| 16033622 | 2005 | Review | Int J Clin Pract | Describes pimecrolimus's effects on T cells and mast cells and its potential beyond atopic dermatitis |
| 20000875 | 2010 | Open-label study | Am J Clin Dermatol | Pimecrolimus 1% cream effective and well tolerated in resistant facial seborrheic dermatitis |
| 17982237 | 2007 | Open-label study | J Korean Med Sci | 20 Korean patients applied pimecrolimus 1% cream for 4 weeks for facial seborrheic dermatitis |
| 17020422 | 2006 | Review | Expert Opin Pharmacother | Pimecrolimus has potential in inflammatory skin diseases other than atopic dermatitis |
| 19213227 | 2009 | Review | J Drugs Dermatol | Current status and therapeutic options for facial seborrheic dermatitis |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12179P | ELIDEL CREAM 1% w/w | Cream | Not stated in the licence record |
Elidel is a single-ingredient topical cream. It is currently valid, and the Singapore register shows no cancelled registrations.
Safety Considerations
- Contraindications flagged in the drug knowledge graph (not label text): common wart, epidermodysplasia verruciformis, anogenital human papillomavirus infection, herpes simplex, herpes simplex dermatitis, herpes zoster, chickenpox, infectious mononucleosis, chronic Epstein-Barr virus infection syndrome, lymphatic system disease, Netherton syndrome, and ichthyosis linearis circumflexa. Overall, viral skin infections, lymphatic disease, and skin-barrier disorders are the main concerns.
- Drug interactions: The interaction screen returned 100 records. The 20 listed (e.g., pantoprazole, omeprazole, doxycycline, metformin, simvastatin, prednisone, triamcinolone, hydrocortisone, budesonide, aspirin) have no severity grading ("Unknown"), so their clinical significance is unconfirmed.
- Class-level concerns from the literature: Topical calcineurin inhibitors carry a boxed warning on long-term use and malignancy (including lymphoma) concerns, and use in infants is limited. A 2023 systematic review and meta-analysis examined cancer risk with pimecrolimus and tacrolimus, and a 5-year randomized trial in infants provides long-term safety data. Pimecrolimus can also mask tinea (tinea incognito) and cause skin irritation if combined with alcohol intake.
The Singapore package insert warnings and contraindications have not yet been obtained. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 randomized trial and two systematic reviews of randomized trials directly support pimecrolimus in seborrheic dermatitis, and the mechanism overlaps with its established atopic dermatitis use. However, the direct clinical evidence is limited to one short Phase 2 study, no Phase 3 trial exists for this indication, and Singapore safety label data are missing.
To proceed, the following is needed:
- Singapore package insert (warnings, contraindications, boxed-warning language), which is a blocking data gap for safety screening
- Detailed mechanism of action data from DrugBank
- Confirmation of the Singapore approved indication wording, which is blank in the licence record
- Review of Phase 2 trial results and the primary RCT data underlying the systematic reviews
- A confirmatory, longer-duration controlled study, with a plan for limiting duration of use, avoiding infants, and monitoring for infection and malignancy
- Interaction severity grading for the co-medications flagged
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.